CELH
Celsius Holdings, Inc.
CELH has the edge over CHSCN overall, supported by stronger fundamentals and stronger valuation.
CHSCN
CHS Inc.
CHSCN trails on the overall score without a compensating advantage in the available component scores.
CELH Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Stable | |
| Strong |
CELH's revenue, profitability and balance sheet are currently healthy, and its cash flow is stable.
CHSCN Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Stable | |
| Stable | |
| Healthy |
CHSCN's revenue and balance sheet are currently healthy, and its profitability and cash flow are stable.
CELH PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 21x | $31.89 | — |
| Current | 35x | $31.89 | — |
| Cheap | 40x | $35.95 | +13% |
| Fair | 141x | $127 | +299% |
| Expensive | 650x | $585 | +1735% |
Historical ranges are pointers, not guarantees.
CELH's PE is in its cheap range at 35x. If earnings grow as analysts expect, today's price would be 21x next year's earnings.
CHSCN PE Valuation
CHSCN has no meaningful PE right now: it lost money over the past year.
CELH Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Growth | |
| Improving | |
| Limited | |
| Low |
Analysts expect earnings and revenue growth for CELH, with profitability improving. However, they disagree widely on these estimates.
CHSCN Forward outlook
There aren't enough analyst estimates for CHSCN to show an outlook.
CELH Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $1.53 | +70% |
| Q3 2026 | $0.90 | +718% |
| Q2 2026 | $0.24 | -37% |
| Q1 2026 | $0.43 | +30% |
| Q4 2025 | $0.25 | -44% |
| Q3 2025 | $0.11 | -85% |
| Q2 2025 | $0.38 | -62% |
| Q1 2025 | $0.33 | -64% |
| Q4 2024 | $0.45 | -42% |
CELH earned $0.90 per share over the past year, about eight times what it earned the year before.
CHSCN Earnings Per Share
CHSCN and CELH do not have enough comparable growth data to identify a winner.
CELH Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $847.2M | +17% |
| Q2 2026 | $817.9M | +11% |
| Q1 2026 | $782.6M | +138% |
| Q4 2025 | $721.6M | +117% |
| Q3 2025 | $725.1M | +173% |
| Q2 2025 | $739.3M | +84% |
| Q1 2025 | $329.3M | -7.4% |
| Q4 2024 | $332.2M | -4.4% |
CELH has the edge over CHSCN on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 20% | +31 points |
| Q2 2026 | 9.2% | -10 points |
| Q1 2026 | 18% | +2 points |
| Q4 2025 | 3.6% | +9.2 points |
| Q3 2025 | -11% | -9.8 points |
| Q2 2025 | 19% | -4.1 points |
| Q1 2025 | 16% | -7.6 points |
| Q4 2024 | -5.6% | -23 points |
CELH has the edge over CHSCN on profitability, with a higher operating margin.
CHSCN Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $10.4B | +21% |
| Q2 2026 | $11.6B | +19% |
| Q1 2026 | $8.4B | +7.2% |
| Q4 2025 | $8.9B | -4.6% |
| Q3 2025 | $8.6B | -6.2% |
| Q2 2025 | $9.8B | +1.6% |
| Q1 2025 | $7.8B | -14% |
| Q4 2024 | $9.3B | -18% |
CHSCN's revenue is recovering but still below its 2022 peak: $10.4B last quarter, up 21% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 5.8% | +5.2 points |
| Q2 2026 | 0.9% | +0.2 points |
| Q1 2026 | -2.9% | -0.7 points |
| Q4 2025 | 1.4% | -0.1 points |
| Q3 2025 | 0.6% | +0.9 points |
| Q2 2025 | 0.7% | -0.9 points |
| Q1 2025 | -2.2% | -3 points |
| Q4 2024 | 1.5% | -2 points |
CHSCN's operating margin was 5.8% last quarter, up 5.2 points from the same quarter a year ago, near the top of its range since 2019.
CELH Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $127.7M | -60% |
| Q2 2026 | $205.5M | +479% |
| Q1 2026 | $65.8M | -32% |
| Q4 2025 | -$130M | -285% |
| Q3 2025 | $321.5M | +3599% |
| Q2 2025 | $35.5M | +17% |
| Q1 2025 | $96.4M | -26% |
| Q4 2024 | $70.3M | +16394% |
CELH still generates free cash flow, though less than at its 2025 peak: $269M over the past year.
CHSCN Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $1.3B | +17% |
| Q2 2026 | $984.7M | +89% |
| Q1 2026 | -$674M | +$528.8M |
| Q4 2025 | -$453.8M | +$32.8M |
| Q3 2025 | $1.1B | +27% |
| Q2 2025 | $520.6M | +44% |
| Q1 2025 | -$1.2B | -$749.5M |
| Q4 2024 | -$486.6M | -$196.6M |
CHSCN has the edge over CELH on cash flow, with more consistent year-over-year improvement.
CELH Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.8% | -2M shares |
| 1 year | -1.1% | -2.9M shares |
| 3 years | +7.4% | +17.6M shares |
| 5 years | +8.3% | +19.5M shares |
| Available history | +32% | +62.4M shares |
CELH has 255M diluted shares, down 1.1% from a year ago.
| Quarter | Spent |
|---|---|
| Q3 2026 | $300,000 |
| Q2 2026 | $1M |
| Q1 2026 | $8.8M |
| Q4 2025 | $2.5M |
| Q3 2025 | $448,000 |
| Q2 2025 | $879,000 |
| Q1 2025 | $1.9M |
| Q4 2024 | $603,000 |
CELH spent $13M buying back its own shares over the past year, about three times what it spent the year before.
CHSCN Total Shares
CELH Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -0.1x | Net Cash |
| Q2 2026 | 0.2x | Very low |
| Q1 2026 | 0.5x | Very low |
| Q4 2025 | 1.6x | Healthy |
| Q3 2025 | 0.5x | Very low |
| Q2 2025 | 1.4x | Healthy |
| Q1 2025 | -7.3x | Net Cash |
| Q4 2024 | -5.5x | Net Cash |
CELH has the edge over CHSCN on leverage, with a lower net debt burden relative to earnings.
CHSCN Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.4x | Healthy |
| Q2 2026 | 2.2x | Moderate |
| Q1 2026 | 2.7x | Moderate |
| Q4 2025 | 1.9x | Healthy |
| Q3 2025 | 2.0x | Moderate |
| Q2 2025 | 3.2x | Elevated |
| Q1 2025 | 2.7x | Moderate |
| Q4 2024 | 2.1x | Moderate |
CHSCN's net debt is about 1.4 years of its operating earnings (EBITDA), down from 2.0 years a year ago.
CELH Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 51.3 | Neutral |
| Stochastic | 56.8 | Neutral |
CELH's weekly RSI is 51 (neutral) and its Stochastic is 57 (neutral).
CHSCN Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 20.2 | Oversold |
| Stochastic | 9.9 | Oversold |
CHSCN's weekly RSI is 20 (oversold) and its Stochastic is 10 (oversold).
CELH PE vs Consumer Defensive Sector
| Metric | CELH | Sector median | Relative |
|---|---|---|---|
| PE | 35x | 19x | 82% above |
| PE % | 11 | 18 | 7 pts below |
CELH is trading at 35x earnings, a 82% premium to the Consumer Defensive sector's median of 19x.
CHSCN PE vs Consumer Defensive Sector
CHSCN has no meaningful PE right now: it lost money over the past year.
CELH Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $29.1 | 9.4% above |
| 20 week MA | $29.6 | 7.8% above |
| 50 week MA | $36.1 | 12% below |
| 100 week MA | $38.8 | 18% below |
| 200 week MA | $44.6 | 29% below |
CELH has the edge over CHSCN on trend strength, trading above more of its moving averages.
CHSCN Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $23.6 | 6.5% below |
| 20 week MA | $24.5 | 9.9% below |
| 50 week MA | $24.9 | 12% below |
| 100 week MA | $25.1 | 12% below |
| 200 week MA | $25.3 | 13% below |
CHSCN is in a downtrend: it's below all five of its weekly moving averages, and 13% below its 200-week average.
CELH Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $1.58 | $14.7 | +832% |
| 2021 | $14.7 | $24.9 | +69% |
| 2022 | $24.9 | $35.6 | +43% |
| 2023 | $35.6 | $54.5 | +53% |
| 2024 | $54.5 | $26.5 | -51% |
| 2025 | $26.5 | $45.6 | +72% |
| 2026 YTD | $45.6 | $31.9 | -30% |
CELH's yearly returns have swung widely, from +832% in 2020 to −51% in 2024. It's down 30% so far in 2026.
CHSCN Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $27.0 | $27.8 | +2.9% |
| 2021 | $27.8 | $27.5 | -1% |
| 2022 | $27.5 | $24.7 | -10% |
| 2023 | $24.7 | $25.0 | +1.3% |
| 2024 | $25.0 | $25.0 | +0.2% |
| 2025 | $25.0 | $24.9 | -0.5% |
| 2026 YTD | $24.9 | $22.1 | -11% |
CHSCN has the edge over CELH on returns for 2026, with the stronger performance.